miR‐32533 ameliorates AD‐like cognitive impairment and suppresses the accumulation of Aβ from monomers and oligomers to extracellular plaques by modulating the ADAM10/sAPPα processing in the non‐amyloidogenic pathway and BACE1/PS1/sAPPβ signaling in the amyloidogenic pathway, which is attributed to the targeting of CREB5 via its transcription mechanisms. Here, CREB5 is linked to Alzheimer disease.